Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strategy

Precision BioSciences is advancing its gene-editing pipeline, including updates to the ELIMINATE-B trial and oncology collaborations, keeping the small-cap biotech on the radar of speculative healthcare investors.

Precision BioSciences is back in focus after recent clinical and pipeline updates in its gene-editing programs, including the expansion of the ELIMINATE-B trial in hepatitis B and progress in oncology collaborations, according to company communications and sector reports such as FirstWord Pharma as of 03/2025 and information on the company’s investor site Precision BioSciences investor relations as of 03/2025.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Precision BioSciences
• Sector/industry: Biotechnology, gene editing
• Headquarters/country: Durham, North Carolina, USA
• Core markets: Gene-edited cell therapies and in vivo gene-editing candidates for oncology and infectious diseases
• Key revenue drivers: Collaboration income from pharmaceutical partners and potential future product royalties
• Home exchange/listing venue: Nasdaq (ticker: DTIL)
• Trading currency: USD

Precision BioSciences: core business model

Precision BioSciences focuses on gene editing using its proprietary ARCUS platform, which is based on a modified homing endonuclease designed to create targeted double-strand breaks in DNA. The company aims to use this technology for both ex vivo cell therapies and in vivo gene-editing approaches to correct or disable disease-driving genes in patients, according to company descriptions on its website Precision BioSciences website as of 03/2025.

In oncology, Precision BioSciences has worked on allogeneic CAR-T candidates, where donor T cells are engineered using ARCUS to target specific cancer antigens. These off-the-shelf cell therapies are intended to be manufactured at scale and stored for use across multiple patients, in contrast to autologous approaches that rely on each patient’s own cells, as discussed in company presentations summarized by FirstWord Pharma as of 02/2025.

Beyond cancer, the company is developing in vivo gene-editing candidates delivered via viral or non-viral vectors directly into the body. One key focus is chronic hepatitis B, where Precision BioSciences is studying whether ARCUS nucleases can inactivate viral DNA reservoirs in liver cells, with early-stage data from the ELIMINATE-B program forming the basis for recent trial-expansion decisions referenced by FirstWord Pharma as of 03/2025.

Main revenue and product drivers for Precision BioSciences

As a clinical-stage biotech, Precision BioSciences currently generates the majority of its revenue from collaborations with larger pharmaceutical and biotech partners rather than from marketed products. These partnerships typically involve upfront payments, research funding, and potential milestone and royalty streams tied to the success of gene-editing programs, according to details shared in past quarterly reports on the company’s investor site Precision BioSciences investor relations as of 11/2024.

The company’s oncology portfolio includes allogeneic CAR-T candidates targeting antigens such as CD19 and BCMA, which are relevant in blood cancers like certain leukemias and multiple myeloma. While some programs have been restructured or partnered over time, progress in Phase 1/2 trials and the ability to show durable responses with manageable safety profiles remain key potential value drivers that investors track through clinical updates and conference presentations, as reflected in summaries from FirstWord Pharma as of 02/2025.

In the infectious disease area, the ELIMINATE-B program for chronic hepatitis B is an important in vivo gene-editing initiative. Precision BioSciences has moved to expand this trial after early clinical experience, signaling management’s confidence in the underlying approach and safety profile, according to coverage compiled by FirstWord Pharma as of 03/2025. For long-term shareholders, any demonstration that ARCUS can achieve durable reductions in viral markers could be a key inflection point.

Because Precision BioSciences is not yet profitable, cash runway and funding plans are closely watched by the market. Management has used equity offerings and collaborations in previous years to extend its runway, as indicated in earlier SEC filings available through the investor portal Precision BioSciences investor relations as of 11/2024. The balance between advancing multiple programs and preserving capital is a recurring theme in its strategic updates.

Why Precision BioSciences matters for US investors

Precision BioSciences is listed on Nasdaq under the ticker DTIL, placing it within the universe of US-listed gene-editing and cell therapy stocks that are often followed by growth-oriented and biotech-focused investors. As part of the US healthcare innovation ecosystem, the company competes for capital and attention alongside larger players, and its news flow can contribute to volatility in the broader small-cap biotech segment, according to sector overviews from FirstWord Pharma as of 02/2025.

US investors often look at clinical catalysts, such as data presentations at major oncology and liver disease congresses, when assessing gene-editing names. For Precision BioSciences, updates on the ELIMINATE-B trial and any new collaborations are particularly relevant in this context, as highlighted in commentary from FirstWord Pharma as of 03/2025. These events can influence expectations regarding the company’s ability to secure additional funding or partnership support.

In addition, macro factors such as interest rates, risk appetite for pre-revenue biotech, and regulatory sentiment on gene editing in the United States play an important role. Small-cap names like Precision BioSciences can experience pronounced share price swings around financing announcements or trial readouts, and this sensitivity is a key consideration for US-based portfolios with exposure to innovative therapeutics, according to historical trading patterns visible on Nasdaq data services cited by Precision BioSciences investor relations as of 11/2024.

Conclusion

Precision BioSciences is a clinical-stage biotech focused on ARCUS-based gene editing, with programs in oncology and chronic hepatitis B that have prompted recent trial expansions and collaboration updates. For investors, the stock represents exposure to potentially transformative therapies but also to the typical risks of early-stage drug development, including trial uncertainty, funding needs, and competition from larger gene-editing peers. How the company manages its pipeline focus, capital allocation, and partnerships in the coming years is likely to play a central role in determining its long-term value on Nasdaq and its appeal to US and international healthcare investors.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.